Stathmin in cell proliferation and cancer progression

Cancer Genomics and Proteomics

Volumn 2, Issue 4, 2005, Pages 227-237

  Sherbet, G V ^a,b   Cajone, F ^c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Cancer progression; Cell cycle regulation; Cell motility; Cell proliferation; Extracellular matrix; Growth factors; Heat shock proteins; Invasion; Metastasis; Microtubule dynamics; nm23; Prognosis; S100A4; Signal transduction; Suppressor genes

Indexed keywords

HEAT SHOCK PROTEIN; PHOSPHOPROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; SCLEROPROTEIN; STATHMIN;

APOPTOSIS; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; GENE INACTIVATION; HUMAN; METASTASIS; MICROTUBULE; MORPHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION;

EID: 22644432165     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Bieche I, Maucuer A, Laurendeau I, Lachkar S, Spano AJ, Frankfurter A, Levy P, Manceau V, Sobel A, Vidaud M and Curmi PA: Expression of stathmin family genes in human tissues: non-neural-restricted expression for SCLIP. Genomics 81: 400-410, 2003.
2. Segerman B, Holmfeldt P, Morabito J, Cassimeris L and Gullberg M: Autonomous and phosphorylation-responsive microtubule-regulating activities of the N-terminus of Op18/stathmin. J Cell Sci 116: 197-205, 2003.
3. Steinmetz MO, Jahnke W, Towbin H, Garcia-Echeverria C, Voshol H, Muller D and van Oostrum J: Phosphorylation disrupts the central helix in Op18/stathmin and suppresses binding to tubulin. EMBO Rep 2: 505-510, 2001.
4. Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P, Morrione A, Canzonieri V and Colombatti A: p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 7: 51-63, 2005.
5. Walter-Yohrling, Cao XH, Callahan M, Weber W, Morgenbesser S, Madden SL, Wang C and Teicher BA: Identification of genes expressed in malignant cells that promote invasion. Cancer Res 63: 8939-8947, 2003.
6. Brattsand G, Roos G, Marklund U, Ueda H, Landberg G, Nanberg E, Sideras P and Gullberg M: Quantitative analysis of the expression and regulation of an activation regulated phosphoprotein (oncoprotein 18) in normal and neoplastic cells. Leukemia 7: 569-579, 1993.
7. Price DK, Ball JR, Bahrani-Mostafavi Z, Vachris JC, Kaufman JS, Naumann RW, Higgins RV and Hall JB: The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. Cancer Invest 18: 722-730, 2000.
8. Alaiya AA, Franzen B, Fujioka K, Moberger B, Schedvins K, Silversvard C, Linder S and Auer G: Phenotypic analysis of ovarian carcinoma: polypeptide expression in benign, borderline and malignant tumours. Int J Cancer 73: 678-683, 1997.
9. Sherbet GV and Patil DB: Molecular progression of ovarian cancer. In: Molecular and Cellular Pathology of Cancer Progression and Prognosis, Sherbet GV (ed.). Transworld Research Network, Trivandrum, 2005.
10. Brattsand G: Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer 83: 311-318, 2000.
11. Curmi PA, Nogues C, Lachkar S, Carelle N, Gonthier MP, Sobel A, Lidereau R and Bieche I: Overexpression of stathmin in breast carcinomas points to highly proliferative tumours. Br J Cancer 82: 142-150, 2000.
12. Mistry SJ and Atweh GF: Stathmin expression in immortalized and oncogene transformed cells. Anticancer Res 19: 573-577, 1999.
13. Prasad SC, Thraves PJ, Soldatenkov VA, Varghese S and Dritschilo A: Differential expression of stathmin during neoplastic conversion of human prostate epithelial cells is reversed by hypomethylating agent, 5-azacytidine. Int J Oncol 14: 529-534, 1999.
14. Friedrich B, Gronberg H, Landstrom M, Gullberg M and Bergh A: Differentiation-stage specific expression of oncoprotein-18 in human rat prostatic adenocarcinoma. Prostate 27: 102-109, 1995.
15. Rabilloud T, Berthier R, Valette C, Garin J and Lawrence LJ: Induction of stathmin expression during erythropoietic differentiation. Cell Growth Differ 6: 1307-1314, 1995.
16. Hoelscher SR and Ascoli M: Leydig tumour-cell protein phosphorylated in response to stimulation with choriogonadotropin or epidermal growth factor is indentified as stathmin. Endocrinology 135: 662-666, 1994.
17. Hummert TW, Schwartz Z, Sylvia VL, Dean DD and Boyan BD: Stathmin levels in growth plate chondrocytes are modulated by vitamin D-3 metabolites and transforming growth factor-beta 1 and are associated with proliferation. Endocrine 15: 93-101, 2001.
18. Hannan AJ, Henke RC, Weinberger RP, Sentry JW and Jeffrey PL: Differential induction and intracellular localization of SCG10 messenger RNA is associated with neuronal differentiation. Neuroscience 72: 889-900, 1996.
19. Pellier-Monnin V, Astic L, Bichet S, Riederer BM and Grenningloh G: Expression of SCG10 and stathmin proteins in the rat olfactory system during development and axonal regeneration. J Comp Neurol 433: 239-254, 2001.
20. DiPaolo G, Pellier V, Catsicas M, Antonsson B, Catsicas S and Grenningloh G: The phosphoprotein stathmin is essential for nerve growth factor-stimulated differentiation. J Cell Biol 133: 1383-1390, 1996.
21. Takekoshi K, Nomura F, Isobe K, Motooka M, Nammoku T and Nakai T: Identification and initial characterization of stathmin by the differential display method in nerve growth factor-treated PC12 cells. Eur J Endocrinol 138: 707-712, 1998.
22. Drouva SV, Poulin B, Manceau V and Sobel A: Luteinizing hormone-releasing hormone-signal transduction and stathmin phosphorylation in the gonadotrope alpha T3-1 cell line. Endocrinology 139: 2235-2239, 1998.
23. Okazaki T, Himi T, Peterson C and Mori N: Induction of stathmin messenger RNA during liver regeneration. FEBS Lett 336: 8-12, 1993.
24. Rowlands DC, Harrison RF, Jones NA, Williams A, Hubscher SG and Brown G: Stathmin is expressed by the proliferating hepatocytes during liver regeneration. J Clin Pathol Clin Mol Pathol 48: M88-M92, 1995.
25. Egnaczyk GF, Pomonis JD, Schmidt JA, Rogers SD, Peters C, Ghilardi JR, Mantyh PW and Maggio JE: Proteomic analysis of the reactive phenotype of astrocytes following endothelin-1 exposure. Proteomics 3: 689-698, 2003.
26. Meyer N, Prentice DA, Fox MT and Hughes JP: Prolactin-induced proliferation of the Nb2 T-lymphoma is associated with protein kinase C-dependent phosphorylation of stathmin. Endocrinology 131: 1977-1984, 1992.
27. Ji H. Baldwin GS, Burgess AW, Moritz RL, Ward LD and Simpson RJ: Epidermal growth factor induces serine phosphorylation of stathmin in a human colon carcinoma cell line (LIM-1215). J Biol Chem 268: 13396-13405, 1993.
28. Mimics ZK, Caudell E, Gao Y, Kuwahara K, Sakaguchi N, Kurosaki T, Burnside J, Mimics K and Corey SJ: Microarray analysis of Lyn-deficient B cells reveals germinal center-associated nuclear protein and other genes associated with the lymphoid germinal center. J Immunol 172: 4133-4141, 2004.
29. Jourdain L, Curmi P, Sobel A, Pantaloni D and Carlier MF: Stathmin: A tubulin-sequestering protein which forms a ternary T2S complex with two tubulin molecules. Biochemistry 36: 19817-10821, 1997.
30. Charbaut E, Curmi PA, Ozon S, Lachkar S, Redeker V and Sobel A: Stathmin family proteins display specific molecular and tubulin binding properties. J Biol Chem 276: 16146-16154, 2001.
31. Sherbet GV: Genetic Recombination in Cancer. Academic/Elsevier, London, 2003.
32. Sherbet GV: DNA ploidy and the progression of cancer. In: Molecular and Cellular Pathology of Cancer Progression and Prognosis, Sherbet GV (ed.). Transworld Research Network, Trivandrum, 2005.
33. Polager S and Ginsberg D: E2F mediates sustained G(2) arrest and down-regulation of stathmin and AIM-1 expression in response to genotoxic stress. J Biol Chem 278: 1443-1449, 2003.
34. Polzin RG, Benlhabib H, Trepel J and Herrera JE: E2F sites in the Op18 promoter are required for high level of expression in the human prostate carcinoma cell line PC-3-M. Gene 341: 209-218, 2004.
35. Vancompernolle K, Boonefaes T, Mann M, Fiers W and Grooten J: Tumor necrosis factor-induced microtubule stabilization mediated by hyperphosphorylated oncoprotein 18 promotes cell death. J Biol Chem 275: 33876-33882, 2000.
36. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ and George DL: Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13: 2490-250, 1999.
37. Johnsen JI, Aurelio ON, Kwaja Z, Jorgensen GE, Pellegata NS, Plattner R, Stanbridge EJ and Cajot JF: p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. Int J Cancer 88: 695-691, 2000.
38. Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ and George DL: Down-regulation of the stathmin/Op18 and FKB25 genes following p53 induction. Oncogene 18: 5954-5958, 1999.
39. Sablina AA, Chumakov PM, Levine AJ and Kopnin BP: p53 activation in response to microtubule disruption is mediated by integrin-Erk signaling. Oncogene 20: 899-909, 2001.
40. Giannakakou P, Sackett DL, Ward Y, Webster KR, Blagosklonny MV and Fojo T: P53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nature Cell Biol 2: 709-717, 2000.
41. Morris VB, Brammall J, Noble J and Reddel R: P53 localizes to the centrosomes and spindles of mitotic cells in the embryonic chick epiblast, human cell lines, and a human primary culture: an immunofluorescence study. Exp Cell Res 256: 122-130, 2000.
42. Ciciarello M, Mangiacasale R, Casenghi M, Limongi MZ, D'Angelo M, Soddu S, Lavia P and Cundari E: p53 displacement from centrosomes and p53-mediated G(I) arrest following transient inhibition of the mitotic spindle. J Biol Chem 276: 19205-19213, 2001.
43. Khan SH and Wahl GM: p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G(I) arrest. Cancer Res 58: 396-401, 1998.
44. Galmarini CM, Kamath K, Vanier-Viornery A, Hervieu V, Peiller E, Palette N, Puisieux A, Jordan MA and Dumontet C: Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br J Cancer 88: 1793-1799, 2003.
45. Parker C, Lakshmi MS, Piura B and Sherbet GV: Metatasis associated mts1 gene expression correlates with increased p53 detection in the B16 murine melanoma cells. DNA Cell Biol 13: 343-351, 1994.
46. Chen HL, Fernig DG, Rudland PS, Sparks A, Wilkinson MC and Barraclough R: Binding to intracellular targets of the metastasis-inducing protein, S100A (p9Ka). Biochem Biophys Res Commun 286: 1212-1217, 2001.
47. Cajone F and Sherbet GV: Stathmin is involved in S100A4-mediated regulation of cell cycle progression. Clin Exptl Metastasis 17: 865-871, 1999.
48. Agoff SN, Hou J, Linzer DIH and Wu B: Regulation of human HSP70 promoter. Science 259: 84-87, 1993.
49. Tsutsumiishii Y, Todokoro K, Kanaoka F and Tsuchida N: Response of heat shock element within the human HSP70 promoter to mutated p53 genes. Cell Growth Differentiation 6: 1-8, 1995.
50. He CY, Merrick BA, Patterson RM and Selkirk JK: Altered protein synthesis in p53 null and hemizygotic transgenic mouse embryonic fibroblasts. Appl Theoret Electrophoresis 5: 15-24, 1995.
51. Sherbet GV and Lakshmi MS: The Genetics of Cancer, Acadmic/Elsevier, London, 1997.
52. Cajone F, Debiasi S, Parker C, Lakshmi MS and Sherbet GV: Metastasis associated mts1 gene is down-regulated by heat shock in variant cell lines of the B16 murine melanoma. Melanoma Res 4: 143-150, 1994.
53. Sherbet GV, Cajone F, Albertazzi E and Lakshmi MS: Induction of heat shock protein HSP28 and down-regulation of 18A2/mts1 gene are associated with inhibition of proliferation of B16 murine melanoma cell lines. Proc Amer Assoc Cancer Res 37: 74, 1996.
54. Saito Y, Yamagishi N, Ishihara K and Hatayama T: Identification of alpha-tubulin as an Hsp105 alpha-binding protein by the yeast two-hybrid system. Exp Cell Res 256: 233-240, 2003.
55. Izawa I, Nishizawa M, Ohtakara K, Ohtsuka K, Inada H and Inagaki M: Identification of Mrj, a DnaJ/Hsp40 family protein, as a keratin 8/18 filament regulatory protein. J Biol Chem 275: 34521-34527, 2000.
56. Cambiazo V, Gonzalez M, Isamit C and Maccioni RB: The beta-isoform of heat shock protein hsp-90 is structurally related with human microtubule-interacting protein Mip-90. FEBS Lett 457: 343-347, 1999.
57. Bluhm WF, Martin JL, Mestril R and Dillmann WH: Specific heat shock proteins protect microtubules during simulated ischemia in cardiac myocytes. Am J Physiol Heart Circul Physiol 44: H2243-H2249, 1998.
58. Gache V, Louwagie M, Garin J, Caudron N, Lafanechere L and Valiron O. Identification of proteins binding the native tubulin dimer. Biochem Biophys Re Commun 327: 35-42, 2005.
59. Gamier C, Barbier P, Gilli R, Lopez C, Peyrot V and Briand C: Heat-shock protein 90 (hsp90) binds in vitro to tubulin dimer and inhibits microtubule formation. Biochem Biophys Res Commun 250: 414-419, 1998.
60. Fujimoto M, Nagasaka Y, Tanaka T and Nakamura K: Analysis of heat shock-induced monophosphorylation of stathmin in human T lymphoblastic cell line Jurkat by two-dimensional gel electrophoresis. Electrophoresis 19: 2515-2520, 1998.
61. Beretta L, Duboia MF, Sobel A and Bensaude O: Stathmin is a major substrate for mitogen-activated protein kinase during heat shock and chemical stress. Eur J Biochem 227: 388-395, 1995.
62. Larsson N, Marklund U, Gradin HM, Brattsand G and Gullberg M: Control of microtubule dynamics by oncoprotein 18. Dissection of the regulatory role of multisite phosphorylation during mitosis. Mol Cell Biol 17: 5530-5539, 1997.
63. Manceau V, Gavet O, Curmi P and Sobel A: Stathmin interaction with HSC70 family proteins. Electrophoresis 20: 409-417, 1999.
64. Strey CW, Spellman D, Stieber A, Gonatas JO, Wang XS, Lambris JD and Gonatas NK: Dysregulation of stathmin, a microtubule-destabilizing protein, and up-regulation of Hsp25, Hsp27, and the antioxidant peroxiredoxin 6 in a mouse model of familial amyotrophic lateral sclerosis. Am J Pathol 165: 1701-1718, 2004.
65. Gomez TM and Letourneau PC: Filopodia initiate choices made by sensory neuron growth cones at laminin/fibronectin borders in vivo. J Neurosci 14: 5959-5972, 1994.
66. Suh LH, Oster SF, Soehrman SS, Grenningloh G and Sretavan DW: L1/laminin modulation of growth cone response to EphB triggers growth pauses and regulates the microtubule destabilizing protein SCG10. J Neurosci 24: 1976-1986, 2004.
67. Balogh A, Mege RM and Sobel A: Growth and cell density-dependent expression of stathmin in C2 myoblasts in culture. Exp Cell Res 224: 8-15, 1996.
68. Wittmann T, Bokoch GM and Waterman-Storer CM: Regulation of microtubule destabilizing activity of Op18/stathmin downstream of Rac1. J Biol Chem 279: 6196-6203, 2004.
69. Zhou J, Jezova M, Elkahloun AG and Saavedra JM: Angiotensin II AT(1) receptor antagonism downregulates stress-related gene expression in brain microvessels from spontaneously hypertensive and normotensive rats. Ann NY Acad Sci 1018: 480-486, 2004.
70. Bertrand MJ, Deramaudt M, Remy P and Abraham NG: Upregulation of human heme oxygenase gene expression by Ets-family proteins. J Cell Biochem 72: 311-321, 1999.
71. Miyashita H, Kanemura M, Yamazaki T, Abe M and Sato Y: Vascular endothelial zinc finger 1 is involved in the regulation of angiogenesis: Possible contribution of stathmin/OP18 as a downstream target gene. Arterioscler Thromb Vasc Biol 24: 878-884, 2004.
72. Chen G, Wang H, Gharib TG, Huang CC, Thomas DG, Shedden KA, Kuick R, Taylor JMG, Kardia SLR, Misek DE, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM and Beer DG: Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol Cell Proteomics 2: 107-116, 2003.
73. Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, Golanov A, Joos S and Lichter P: Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 64: 3103-3111, 2004.
74. Balachandran R, Welsh MJ and Day BW: Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells. Oncogene 22: 8924-8930, 2003.
75. Alli E, Bash-Babula J, Yang JM and Hait WN: Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 62: 6864-6869, 2002.
76. Nishio K, Nakamura T, Koh Y, Kanzawa F, Tamura T and Saijo N: Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells. Cancer 91: 1494-1499, 2001.
77. Rosell R, Scagliotti G, Danenberg KD, Lord RVN, Bepler G, Novello S, Cooc J, Crino L, Sanchez JJ, Taron M, Boni C, De Marinis F, Tonato M, Marangolo M, Gozzelino F, Di Costanzo F, Rinaldi M, Salonga D and Stephens C: Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22: 3548-3553, 2003.
78. Mistry SJ, Bank A and Atweh GF: Anti-angiogenesis therapy: targeting vascular endothelial cells by anti-stathmin adenovirus. Blood 102: 5713, 2003.
79. Iancu C, Mistry SJ, Arkin S and Atweh GF: Taxol and anti-stathmin therapy: a synergistic combination that targets the mitotic spindle. Cancer Res 60: 3537-3541, 2000.
80. Mistry SJ, Benham CJ and Atweh GF: Development of ribozymes that target stathmin, a major regulator of the mitotic spindle. Antisense Nucleic Acid Drug Dev 11: 41-49, 2001.